Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Leukemia

Free Subscription 05.01.2026 1 Acta Haematol 2 Ann Hematol 5 Blood 1 BMC Cancer 1 Br J Cancer 1 Cancer 3 Eur J Haematol 1 Exp Cell Res 2 Exp Hematol 3 Int J Hematol 1 J Biol Chem 2 J Pediatr Hematol Oncol 1 J Virol 4 Leuk Lymphoma 5 Leuk Res 2 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. VALTIS YK, Park JH
   Improving cure rates of B-cell acute lymphoblastic leukemia with chimeric antigen receptor T-cells.
   Acta Haematol. 2025 Dec 31:1-13. doi: 10.1159/000550161.
   PubMed         Abstract available
   
   

   
   Ann Hematol

2. LUO C, Zhang J, Huang X, Wu G, et al
   The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
   Ann Hematol. 2025 Dec 23. doi: 10.1007/s00277-025-06342.
   PubMed         Abstract available
   
   
3. CHEN J, Li J, Wang Z, Huang Z, et al
   Intensified pegylated-asparaginase in consolidation therapy improved outcome of allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia.
   Ann Hematol. 2025 Dec 23. doi: 10.1007/s00277-025-06576.
   PubMed         Abstract available
   
   

   
   Blood

4. KEESHAN K
   Fetal defense against leukemia: a developmental shield.
   Blood. 2026;147:7-8.
   PubMed        
   
   
5. NISHIMURA K, Isobe T, Shigehiro T, Nomura M, et al
   Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.
   Blood. 2025 Dec 29:blood.2024026928. doi: 10.1182/blood.2024026928.
   PubMed         Abstract available
   
   
6. WEI AH, Iland HJ, DiNardo CD, Reynolds J, et al
   Measurable residual disease intervention in AML: a new therapeutic horizon.
   Blood. 2026;147:13-23.
   PubMed         Abstract available
   
   
7. MENDOZA-CASTREJON J, Yang W, Denby E, Wang HC, et al
   Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.
   Blood. 2026;147:61-72.
   PubMed         Abstract available
   
   
8. SIMON F, Ligtvoet R, Bohn JP, Nosslinger T, et al
   Acalabrutinib treatment for older (aged >/=80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.
   Blood. 2025;146:3153-3162.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. BARKHORDAR M, Tavoosi S, Tavakoli S, Salavatipour MS, et al
   Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT.
   BMC Cancer. 2025;25:1931.
   PubMed         Abstract available
   
   

   
   Br J Cancer

10. WACHTMEISTER A, Bang B, Nordgren I, Martling A, et al
    Lifetime risk of solid tumors and leukemia in Down Syndrome: a population-based Swedish matched cohort study.
    Br J Cancer. 2025 Dec 26. doi: 10.1038/s41416-025-03318.
    PubMed         Abstract available
    
    

    
    Cancer

11. 
    Correction to "Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly".
    Cancer. 2026;132:e70232.
    PubMed        
    
    

    
    Eur J Haematol

12. NOURBAKHSH SMK, Valadkhani C, Safaei H
    Clinical and Laboratory Indicators of Pediatric Leukemia and Neuroblastoma in Musculoskeletal Presentations: A Retrospective Study From a Resource-Limited Setting.
    Eur J Haematol. 2025 Dec 29. doi: 10.1111/ejh.70106.
    PubMed         Abstract available
    
    
13. HO TN, Willard P, Murray GF, Liu L, et al
    Improvements in Real-World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment.
    Eur J Haematol. 2025 Dec 23. doi: 10.1111/ejh.70087.
    PubMed         Abstract available
    
    
14. KASMI D, Bisegna ML, Carmosino I, Scalzulli E, et al
    Outpatient Versus Inpatient Azacitidine Plus Venetoclax Regimen in Elderly Acute Myeloid Leukemia: A Multicenter Retrospective Analysis.
    Eur J Haematol. 2025 Dec 21. doi: 10.1111/ejh.70102.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

15. BHAT M, Narasimhan M, Shelar A, Patwardhan R, et al
    p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia.
    Exp Cell Res. 2025;455:114870.
    PubMed         Abstract available
    
    

    
    Exp Hematol

16. GORSCH E, Rudat S, Arnone M, Keppeler H, et al
    Laminin Receptor Characterization in Acute Myeloid Leukemia: Integrin alpha7beta1 Defines leukemic cells with Migratory Potential.
    Exp Hematol. 2025 Dec 25:105363. doi: 10.1016/j.exphem.2025.105363.
    PubMed         Abstract available
    
    
17. MAHDAVI L, Alikarami F, Goodrow H, Lenard A, et al
    Upfront menin-inhibitor resistance in multiply pretreated leukemias.
    Exp Hematol. 2026;153:105268.
    PubMed         Abstract available
    
    

    
    Int J Hematol

18. SAKAI T, Miyao K, Kiwada T, Ozaki S, et al
    Intermediate-dose cytarabine as a safer consolidation strategy for acute myeloid leukemia.
    Int J Hematol. 2025 Dec 26. doi: 10.1007/s12185-025-04141.
    PubMed         Abstract available
    
    
19. MATSUI H, Takizawa J, Kojima K, Tauchi T, et al
    Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.
    Int J Hematol. 2025 Dec 28. doi: 10.1007/s12185-025-04149.
    PubMed         Abstract available
    
    
20. SANO H
    Overweight status and chemotherapy dose modification in pediatric leukemia: disease-specific considerations.
    Int J Hematol. 2025 Dec 28. doi: 10.1007/s12185-025-04154.
    PubMed        
    
    

    
    J Biol Chem

21. WANG Y, Sen-Majumdar A, Li JM, Sarkar S, et al
    Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity.
    J Biol Chem. 2025 Dec 30:111127. doi: 10.1016/j.jbc.2025.111127.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

22. VAJDIC T, Carlson PM, Busch M, Ross BJ, et al
    Successful Resolution of Compartment Syndrome in a Pediatric Patient With B-cell Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol. 2026;48:e47-e50.
    PubMed         Abstract available
    
    
23. RASHEED ZA, Sadeq Musa A, Ibrahim Ashour N, D Salman A, et al
    Assessment of Trace Element Concentrations in the Blood of Pediatric Leukemia Patients.
    J Pediatr Hematol Oncol. 2025 Dec 11. doi: 10.1097/MPH.0000000000003157.
    PubMed         Abstract available
    
    

    
    J Virol

24. CHEN Y, Wu L, Fan W, Wang Y, et al
    MARCH2 inhibits avian leukosis virus replication by targeting gp85 for ubiquitination and degradation.
    J Virol. 2025;99:e0161625.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

25. SWAROOP A, Oh T, Wolniak K, Sukhanova M, et al
    Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.
    Leuk Lymphoma. 2025 Dec 23:1-4. doi: 10.1080/10428194.2025.2604563.
    PubMed        
    
    
26. STAFYLIDIS C, Lakiotaki E, Rougala N, Giannakopoulou N, et al
    Reclassifying T-cell lymphomas in human T-lymphotropic virus 1 carriers: a familial case of adult T-cell leukemia/lymphoma with diagnostic and pathogenetic implications.
    Leuk Lymphoma. 2025 Dec 25:1-5. doi: 10.1080/10428194.2025.2606948.
    PubMed        
    
    
27. HARADA K, Iwata S, Tomita S, Nasukawa M, et al
    Cord blood versus bone marrow/peripheral blood stem cell transplantation under reduced-intensity conditioning in high-risk acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2025 Dec 25:1-13. doi: 10.1080/10428194.2025.2604565.
    PubMed         Abstract available
    
    
28. OKA S, Ueda-Akagi Y, Mitsuyoshi T, Ono K, et al
    Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment.
    Leuk Lymphoma. 2025 Dec 25:1-6. doi: 10.1080/10428194.2025.2604566.
    PubMed         Abstract available
    
    

    
    Leuk Res

29. ZOU M, Wan B, Hu J
    Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial.
    Leuk Res. 2025;160:108148.
    PubMed         Abstract available
    
    
30. RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al
    Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.
    Leuk Res. 2025;160:108153.
    PubMed         Abstract available
    
    
31. OU J, Li J, Liu Q, Zhou H, et al
    Frequency and prognostic significance of RAS pathway alterations in adult acute lymphoblastic leukemia.
    Leuk Res. 2025;160:108155.
    PubMed         Abstract available
    
    
32. STANGANELLI C, Cabrera J, Bender A, Agriello E, et al
    Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients.
    Leuk Res. 2025;160:108151.
    PubMed        
    
    
33. COUCELO M, Sargas C, Ayala R, Larrayoz MJ, et al
    Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.
    Leuk Res. 2025;160:108149.
    PubMed         Abstract available
    
    

    
    Leukemia

34. YANG Y, Liu X, Wei J, Qin J, et al
    In vivo expression of CD3/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)/PD-L1(+) leukemia.
    Leukemia. 2025 Dec 23. doi: 10.1038/s41375-025-02832.
    PubMed         Abstract available
    
    
35. DINH TTT, Lordo MR, Zhang AY, Goda C, et al
    Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.
    Leukemia. 2025 Dec 22. doi: 10.1038/s41375-025-02829.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.